NO743394L - - Google Patents
Info
- Publication number
- NO743394L NO743394L NO743394A NO743394A NO743394L NO 743394 L NO743394 L NO 743394L NO 743394 A NO743394 A NO 743394A NO 743394 A NO743394 A NO 743394A NO 743394 L NO743394 L NO 743394L
- Authority
- NO
- Norway
- Prior art keywords
- glibenclamide
- phenformin
- salt
- preparation according
- hydrochloride
- Prior art date
Links
- 229960004580 glibenclamide Drugs 0.000 claims description 27
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 24
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical class NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 8
- QMNAQPMXDMLOLD-UHFFFAOYSA-N 6-methyl-4-oxo-5,6-dihydrothieno[2,3-b]thiopyran-2-sulfonamide Chemical compound S1C(C)CC(=O)C2=C1SC(S(N)(=O)=O)=C2 QMNAQPMXDMLOLD-UHFFFAOYSA-N 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 229960001753 phenformin hydrochloride Drugs 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- YSUCWSWKRIOILX-UHFFFAOYSA-N 1-(diaminomethylidene)-2-(2-phenylethyl)guanidine;hydrochloride Chemical compound Cl.NC(N)=NC(N)=NCCC1=CC=CC=C1 YSUCWSWKRIOILX-UHFFFAOYSA-N 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 2
- 239000008187 granular material Substances 0.000 description 15
- 229960003243 phenformin Drugs 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 239000001993 wax Substances 0.000 description 7
- 229920002261 Corn starch Polymers 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 229940099112 cornstarch Drugs 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 229940123208 Biguanide Drugs 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 229940100389 Sulfonylurea Drugs 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19732347531 DE2347531A1 (de) | 1973-09-21 | 1973-09-21 | Arzneizubereitungen zur oralen diabetes-behandlung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO743394L true NO743394L (xx) | 1975-04-14 |
Family
ID=5893251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO743394A NO743394L (xx) | 1973-09-21 | 1974-09-20 |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JPS5053521A (xx) |
| AU (1) | AU7349374A (xx) |
| BE (1) | BE820222A (xx) |
| DE (1) | DE2347531A1 (xx) |
| DK (1) | DK496774A (xx) |
| FI (1) | FI274174A (xx) |
| FR (1) | FR2244481A1 (xx) |
| IL (1) | IL45690A0 (xx) |
| NL (1) | NL7412254A (xx) |
| NO (1) | NO743394L (xx) |
| SE (1) | SE7411852L (xx) |
| ZA (1) | ZA745981B (xx) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61260013A (ja) * | 1985-05-14 | 1986-11-18 | Katsumi Takada | 三部分からなる多層錠 |
| KR19980703526A (ko) * | 1995-04-03 | 1998-11-05 | 나가야마오사무 | 수크랄페이트 함유 제제 조성물 |
| AR030920A1 (es) * | 1999-11-16 | 2003-09-03 | Smithkline Beecham Plc | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones |
| FR2816841B1 (fr) * | 2000-11-22 | 2004-02-06 | Lipha | Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation |
| US7964216B2 (en) * | 2001-01-12 | 2011-06-21 | Sun Pharma Advanced Research Company Limited | Spaced drug delivery system |
| ITFI20010230A1 (it) * | 2001-11-29 | 2003-05-29 | Menarini Int Operations Lu Sa | Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii |
-
1973
- 1973-09-21 DE DE19732347531 patent/DE2347531A1/de active Pending
-
1974
- 1974-09-16 NL NL7412254A patent/NL7412254A/xx unknown
- 1974-09-19 FI FI2741/74A patent/FI274174A/fi unknown
- 1974-09-19 AU AU73493/74A patent/AU7349374A/en not_active Expired
- 1974-09-20 SE SE7411852A patent/SE7411852L/ not_active Application Discontinuation
- 1974-09-20 ZA ZA00745981A patent/ZA745981B/xx unknown
- 1974-09-20 DK DK496774A patent/DK496774A/da unknown
- 1974-09-20 NO NO743394A patent/NO743394L/no unknown
- 1974-09-21 JP JP49108328A patent/JPS5053521A/ja active Pending
- 1974-09-22 IL IL45690A patent/IL45690A0/xx unknown
- 1974-09-23 FR FR7432021A patent/FR2244481A1/fr not_active Withdrawn
- 1974-09-23 BE BE148792A patent/BE820222A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA745981B (en) | 1975-10-29 |
| DK496774A (xx) | 1975-05-26 |
| IL45690A0 (en) | 1974-11-29 |
| SE7411852L (xx) | 1975-03-24 |
| JPS5053521A (xx) | 1975-05-12 |
| DE2347531A1 (de) | 1975-04-30 |
| FR2244481A1 (en) | 1975-04-18 |
| NL7412254A (nl) | 1975-03-25 |
| FI274174A (xx) | 1975-03-22 |
| BE820222A (fr) | 1975-03-24 |
| AU7349374A (en) | 1976-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101273981B (zh) | 抗糖尿病制剂以及制药用途 | |
| DE69627883T2 (de) | Zusammensetzung von glibenclamid und metformine zur behandlung von diabetes mellitis typ ii | |
| CN1146427C (zh) | 含有二甲双胍和格列本脲的固体口服剂型 | |
| CN101897696B (zh) | 降糖药物组合物及其用途 | |
| RU2201272C2 (ru) | Применение ингибиторов желудочно-кишечной липазы | |
| FI101040B (fi) | Menetelmä sentraalisten dopamiininpuutostilojen hoitoon tarkoitetun, p eroraalisesti annettavan lääkemuodon valmistamiseksi | |
| JP2005516919A (ja) | 抗糖尿病製剤および方法 | |
| JP2003081870A (ja) | 甲状腺ホルモンの製薬化 | |
| CN104884051A (zh) | 包含吉格列汀和二甲双胍的组合药物及其制备方法 | |
| CN104586834A (zh) | 一种艾帕列净和二甲双胍的药物组合物及其制备方法 | |
| NO743394L (xx) | ||
| CN108697707A (zh) | 包含特力利汀之草酸盐及其溶剂合物之配方 | |
| CN101990427A (zh) | 米格列奈及二甲双胍的复合制剂及其制造方法 | |
| JPH0840906A (ja) | 過血糖症を治療するための薬剤学的製剤 | |
| CN104739835A (zh) | 一种治疗糖尿病的新型药物组合物 | |
| TW586926B (en) | A pharmaceutical composition for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal | |
| CN101897697A (zh) | 降糖药物组合物及用途 | |
| RU2747985C1 (ru) | Твердофазная композиция для коррекции метаболических нарушений при сахарном диабете второго типа | |
| CN109288836B (zh) | 一种复方硫酸双肼屈嗪制剂及其制备方法和应用 | |
| CN105687218A (zh) | 格列吡嗪/阿卡波糖降糖口服制剂组合物及其制备方法 | |
| CN112972480A (zh) | 一种含牛磺熊去氧胆酸、苯丁酸钠的复方散剂/颗粒剂、制备方法、用途以及其药物组合物 | |
| CN112972410A (zh) | 一种西那卡塞药物组合物片剂及其医药用途 | |
| WO2006092711A2 (en) | Extended release tablets of metformin and glipizide | |
| CN104840480B (zh) | 二甲双胍/叶酸/维生素b12药物组合物的新用途 | |
| EP0005733B1 (en) | Pharmaceutical compositions for use in the treatment of diabetic nephropathy and method for preparing them |